frog - If Bayer were working on their own classifier for Baycol, they might run into a problem with DNAPrint's statin response patent. Another thing to consider is that if Bayer were to be able to get Baycol back on the market every week that it's out it would bring in millions per week. If working with DNAPrint would mean getting back out a year or two sooner that would be worth a lot, probably 100's of millions.